Ascentis Independent Advisors Purchases 1,909 Shares of Northrop ...
π Ascentis Independent Advisors boosted its Northrop Grumman holdings by 142.8% in Q1, adding 1,909 shares to a total position of 3,246 shares.
π° Five other institutional investors established new stakes in NOC during the fourth quarter with values ranging from $26,000 to $30,000.
π Institutional ownership of Northrop Grumman stands at 83.40% as of the latest reporting period.
π΅ The company declared a quarterly dividend of $2.47 per share, increasing the annualized yield to 1.8% and maintaining a healthy 30.92% payout ratio.
π Shares of NOC opened at $547.06, trading below its 200-day moving average of $626.92 but above its 50-day moving average of $544.85.
π― BTIG Research restated a buy rating with an increased price target of $815.00 for Northrop Grumman shares.
π UBS Group and Morgan Stanley both lowered their price objectives to $745.00 while maintaining buy or overweight ratings.
ποΈ Wells Fargo initiated coverage on the stock with an overweight rating and a $800.00 price target.
βοΈ Weiss Ratings downgraded Northrop Grumman from a buy to a hold rating, reflecting divergent analyst opinions.
π MarketBeat data indicates an average analyst rating of Moderate Buy with a consensus target price of $698.37.
- Ascentis Independent Advisors increased its position by 142.8% in Q1, signaling strong institutional confidence in the company's long-term prospects.
- Five separate institutional investors established new positions in Northrop Grumman during the fourth quarter, indicating growing interest from smaller funds.
- The company raised its quarterly dividend to $2.47 per share, demonstrating a commitment to returning capital to shareholders and supporting the stock price.
- BTIG Research upgraded its outlook with a buy rating and a high price target of $815.00, suggesting potential upside from current levels.
- Wells Fargo initiated coverage with an overweight rating, validating the company's strategic position in the aerospace and defense sector.
- UBS Group reduced its price objective to $745.00, indicating some analysts see limited near-term upside from current trading levels.
- Morgan Stanley lowered its price target to $745.00, reflecting a more conservative valuation compared to previous estimates.
- Weiss Ratings downgraded the stock from a buy to a hold rating, highlighting concerns about the company's immediate growth trajectory or valuation.
- The stock is trading below its 200-day moving average of $626.92, which may indicate short-term weakness or lack of momentum compared to longer-term trends.